Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
CerebrolysinSmall moleculeNo amino acid sequence. Icon reflects category theme only.Also known as: CERE, FPF-1070
A 2025 meta-analysis of 14 randomized controlled trials (2,884 patients) confirmed that Cerebrolysin improves neurological recovery after ischemic stroke [1]. This porcine brain-derived peptide preparation mimics BDNF, NGF, GDNF, and CNTF, the body's own neurotrophic repair signals. It's approved in over 40 countries for stroke, TBI, and dementia, though not in the United States. The nootropic community treats it differently: healthy adults run 20-day IM courses at 5 mL/day for cognitive sharpness, memory consolidation, and lasting neuroplastic gains that reportedly peak weeks after the last injection.
Fourteen randomized controlled trials. Nearly 3,000 stroke patients. Measurable neurological improvement confirmed by meta-analysis (Patel et al. 2025)[1]. That's the clinical foundation under Cerebrolysin (CAS 12656-61-0), a standardized extract of porcine brain proteins manufactured by EVER Neuro Pharma (EBEWE brand) in Austria. The active fraction is roughly 25% low-molecular-weight neuropeptides and 75% free amino acids, produced through controlled enzymatic proteolysis. Those peptide fragments cross the blood-brain barrier and activate the same signaling cascades as BDNF, NGF, GDNF, and CNTF. In practical terms, it's a biological shortcut to neurotrophic factor activity without requiring gene therapy or recombinant proteins. Clinical use spans stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia across more than 40 countries. Clinicians in Europe and Asia prescribe it routinely; the FDA has never approved it for any indication. The biological complexity of porcine brain hydrolysate makes standardized FDA-pathway approval extremely unlikely regardless of efficacy data. In the biohacking community, Cerebrolysin occupies a unique position. Hundreds of detailed user reports on Longecity and r/Nootropics describe lasting cognitive gains from 20-day IM courses, with effects reportedly peaking 4 to 6 weeks after the final injection. The durability is the consistent theme; this isn't a stimulant-like acute boost. A separate meta-analysis of TBI trials (10 studies, N=8,749)[2] showed improved GCS and GOS scores. The catch: all major Alzheimer's RCTs were manufacturer-funded, and the IM dose community users favor (1,076 mg/day) sits well below the 2,152 to 6,456 mg/day IV range used in clinical trials.
The active peptide fraction in Cerebrolysin is small enough (under 10 kDa) to cross the blood-brain barrier through transcytosis and facilitated transport. Once inside the CNS, these fragments activate the PI3K/Akt and MAPK/ERK signaling pathways, the same cascades triggered by endogenous BDNF, NGF, GDNF, and CNTF. Downstream, this does several things simultaneously. Anti-apoptotic proteins like Bcl-2 get upregulated while pro-apoptotic signals (caspase-3) get suppressed. Neurons that would otherwise die under oxidative stress or ischemic conditions survive. Neurite outgrowth accelerates; dendritic spine density in hippocampal and cortical neurons increases, which is the structural basis for the memory and cognitive improvements seen in trials. Cerebrolysin also modulates acetylcholine, dopamine, and serotonin neurotransmission. That triple-system modulation underlies the reported improvements in memory consolidation, processing speed, and mood. On the neuroinflammation side, it inhibits microglial activation and downregulates pro-inflammatory cytokines (TNF-alpha, IL-1-beta). In ischemic tissue, it attenuates glutamate-induced excitotoxicity and scavenges reactive oxygen species. The multimodal nature of this mechanism is both its strength and the reason it's difficult to characterize in a single-target pharmacological framework.
Moderate-to-strong clinical evidence for acute ischemic stroke: 2025 meta-analysis [1] of 14 RCTs (N=2,884) showed significant NIHSS improvement (MD +1.39, p=0.020); functional independence trend was non-significant. TBI evidence is positive but heterogeneous (10 studies, N=8,749; improved GCS/GOS, no effect on mortality)[2]. Alzheimer's disease: pre-2024 meta-analysis [3] showed superiority over placebo in mild-to-moderate AD, but all major RCTs carry manufacturer funding risk (EBEWE/Ever Pharma). No clinical trials in healthy adults for cognitive enhancement. The biological complexity of porcine brain hydrolysate precludes FDA approval regardless of efficacy.
Patel et al. 2025, "Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 RCTs," Cureus. PMID 41018475. N=2,884; significant NIHSS improvement; no increase in serious adverse events or hemorrhagic transformation.
No evidence in healthy adults: all RCTs used neurological patient populations. AD evidence base has documented manufacturer funding bias; no independent large-scale AD replication. IM route used in community is understudied: clinical trials predominantly use IV infusion. US lyophilized "cerebrolysin" is not the product studied in any RCT (all trials used EBEWE pharmaceutical ampoules). Short-duration trials limit long-term safety and efficacy conclusions.
One of the most consistently praised injectable nootropics in the community. Users report acute cognitive enhancement during the course (Days 3–7) and lasting neuroplastic effects for 1–3 months post-course: the durability of effects is the most consistent theme across hundreds of Longecity and r/Nootropics reports. Primary use is cognitive enhancement and neuroprotection in healthy adults, not stroke/TBI recovery. IM at 5 mL/day is the dominant protocol.
Science and community agree on core neurotrophic mechanisms (BDNF/NGF upregulation, synaptogenesis, neuroprotection). Divergence: community uses IM at 1,076 mg/day: below all clinical trial doses (2,152–6,456 mg/day IV). Community extends use to healthy cognitive enhancement with no RCT evidence in that population. The EBEWE vs. lyophilized sourcing split is a major practical divergence: 100% of clinical evidence uses EBEWE; community in the US often cannot access it.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1076mg | Daily |
| Moderate | 2152mg | Daily |
| Aggressive | 4304mg | Daily |
Cerebrolysin comes as a ready-to-use solution at 215.2 mg/mL in EBEWE ampoules. No reconstitution, no BAC water, no mixing. Open the ampoule, draw, inject. That simplicity is rare for injectable nootropics. For the standard 5 mL IM protocol: one EBEWE 5 mL ampoule equals exactly 1,076 mg. Use a standard 5 mL syringe (not an insulin syringe; the volume is too large). Deltoid injections work with 23 to 25 gauge, 1-inch needles. Gluteal injections need 21 to 23 gauge, 1 to 1.5 inches. The thing most beginners miss: dose before 10 AM. Cerebrolysin has a real stimulating effect, and afternoon dosing wrecks sleep. Also, warm the ampoule to room temperature before drawing; cold solution stings more on injection. A 20-day course at 5 mL/day requires 100 mL total, which is four boxes of five 5 mL ampoules. Budget roughly $270 to $300 per course including international shipping from vendors like RuPharma. Store ampoules at 2 to 8 degrees Celsius. Don't freeze them. Once opened, use immediately; there are no preservatives.
Standard course is 10-21 consecutive daily injections followed by a 3-6 month break. Courses may be repeated 2-4 times per year. Clinical protocols for stroke use 10-day courses; Alzheimer protocols use 20-day courses.
Cerebrolysin cycling is not driven by receptor desensitization or hormonal axis recovery. The rationale is neuroplastic: the compound induces durable structural changes (synaptogenesis, dendritic spine remodeling, BDNF upregulation) that continue to develop for weeks after the last dose. Extended off-periods (3–6 months) allow these structural effects to fully mature and be assessed before repeating. Continuous daily use has no clinical support and may provide diminishing returns as endogenous neurotrophic signaling rebalances. Clinical protocols (approved in 40+ countries) codify 2–4 courses/year maximum based on trial designs, not a known desensitization mechanism.
Or use the universal Peptide Calculator for any peptide.
Expected: Days 1–3: possible acute alertness boost on injection days. Days 4–7: improved mental energy and focus. Weeks 2–3: memory consolidation, faster recall, enhanced cognitive clarity. Post-course weeks 4–12: lasting neuroplastic benefits; many users report peak effects 1–2 months after completing the course.
Monitor: No bloodwork required at this dose for healthy adults. Track cognitive markers (focus, memory, verbal recall) weekly using a simple subjective log. Monitor injection sites for redness, swelling, or induration.
Entrepreneur & Longevity Pioneer
Cerebrolysin is possibly the best neuro-enhancer I've done (subjectively). Can I do more?
Prepare your workspace with alcohol swabs, a 5 mL syringe, and the appropriate needle (23 to 25 gauge for deltoid; 21 to 23 gauge for gluteal).
Allow it to warm to room temperature for 5 to 10 minutes. Inspect: the solution should be clear to slightly yellow. Discard if cloudy or discolored.
Draw the full 5 mL (1,076 mg) into your syringe. Tap out air bubbles and express them.
For deltoid: the fleshy outer part of the upper arm. For gluteal: the upper outer quadrant of the buttock.
Inject slowly over 30 to 60 seconds. Slow injection reduces site pain and dizziness.
Withdraw the needle, apply gentle pressure with a clean swab. Rotate injection sites daily across the 20-day course.
Remain seated for 10 to 15 minutes after injection, especially during the first 3 days when dizziness is most common.
For doses above 5 mL (requiring IV): dilute the Cerebrolysin volume into 100 to 250 mL of 0.9% sodium chloride. Administer via IV drip over 15 to 60 minutes. Never co-infuse with other medications. IV administration requires sterile technique and ideally a trained observer.
Limited to 1,076 mg/day maximum; below all published clinical trial doses. Community-preferred for convenience.
Deltoid (23–25G, 1 inch) or gluteal (21–23G, 1–1.5 inch). Inject slowly. Do not exceed 5 mL per IM injection: tissue injury is confirmed above this volume.
All clinical trial doses (10–30 mL/day) require IV. No dose ceiling on IV route within studied ranges. Faster CNS delivery; more closely replicates trial conditions.
Dilute in 100–250 mL 0.9% NaCl. Infuse over 15–60 minutes. Must use a dedicated saline line: do NOT co-infuse with any other medications. Requires IV access, sterile technique, and ideally an observer for first sessions.
Synergistic BDNF and NGF upregulation; Semax (intranasal) is far simpler to administer and extends neurotrophic signaling between Cerebrolysin courses or during the course itself.
Semax 600 mcg intranasal daily during or between Cerebrolysin courses
Cognitive + anxiolytic complement; Selank adds anxiolytic and mood-stabilizing effects via GABAergic modulation, balancing any overstimulation from Cerebrolysin.
Selank 250–500 mcg intranasal daily during Cerebrolysin course
Classic Longecity stack: racetam-like compound with BDNF/NGF upregulation and neuroprotective properties; commonly combined for additive cognitive enhancement.
10–30 mg oral 1–2x daily during course
Cholinergic support: Cerebrolysin modulates acetylcholine neurotransmission; Alpha-GPC provides substrate to sustain cholinergic activity during course.
300–600 mg oral daily, taken with Cerebrolysin dose
Cerebrolysin modulates dopamine, serotonin, and norepinephrine pathways; concurrent MAOI use creates unpredictable and potentially dangerous neurotransmitter interactions.
Do not combineCerebrolysin is contraindicated in status epilepticus and severe seizure disorders. The interaction between Cerebrolysin and AEDs is unstudied; use in seizure-disorder patients requires neurological supervision.
Physical incompatibility: Cerebrolysin must NOT be mixed in the same IV bag as other drugs including vitamins, cardiovascular agents, or balanced amino acid infusion solutions. Administer in a dedicated saline line only.
Do not combinePricing updated 2026-04-09
MAO inhibitor interaction is the most serious safety concern. Cerebrolysin modulates dopamine, serotonin, and norepinephrine pathways simultaneously. Concurrent MAOI use creates unpredictable and potentially dangerous neurotransmitter accumulation. This combination should be avoided entirely. Seizure risk is real for specific populations. Cerebrolysin is contraindicated in status epilepticus and severe seizure disorders. Patients on antiepileptic drugs should not use Cerebrolysin without neurological supervision, as the interaction between neurotrophic signaling and seizure thresholds has not been studied. Porcine allergy is the other hard stop. Because the preparation is derived from pig brain tissue, anyone with a known allergy to porcine products faces genuine anaphylaxis risk. Hypersensitivity to any component of the preparation is a listed contraindication. Published side effects from controlled clinical trials: Dizziness and vertigo are the most commonly reported adverse events. In clinical trials, overall adverse event rates were comparable to placebo [4]. Community users report the worst dizziness occurs in the first 3 days and usually self-resolves. Injecting slowly (over 60 seconds) and staying seated for 10 to 15 minutes post-injection reduces the severity. Headache, nausea, and sweating appear at rates consistent across the trial literature. These are more common with IV infusion at higher doses (10 to 30 mL/day) than with IM at 5 mL. Agitation and a sensation of warmth are reported at higher IV doses. Community reports describe this as a stimulating quality that can disrupt sleep if dosed after midday. Injection site reactions (pain, redness, swelling) occur with IM administration. Induration lasting beyond 48 hours or worsening should prompt medical evaluation. Transient flu-like symptoms in the first few days of treatment have been reported in a minority of users. SSRI and SNRI interaction monitoring is recommended. Cerebrolysin's serotonin modulation creates a theoretical risk of serotonergic excess when combined with antidepressants. Lithium levels should be monitored closely if co-administered. For pregnancy and breastfeeding: insufficient safety data exists for injectable use. This is a contraindication. When to stop: signs of porcine allergy (rash, urticaria, facial swelling), persistent agitation beyond 3 days, any seizure-like activity, or worsening neurological symptoms. When to see a doctor: any infusion reaction (flushing, chest tightness, breathing difficulty), injection site infection, or unexplained neurological changes during or after a course.
Verify Cerebrolysin dosing and safety with a second opinion
Cerebrolysin carries the highest quality risk of any common injectable nootropic due to a bifurcated market: (1) Pharmaceutical EBEWE ampoules (the only clinically validated product) must be imported internationally with real customs seizure risk and cold-chain integrity concerns; (2) US domestic "cerebrolysin" is typically lyophilized synthetic peptide fractions, not porcine brain hydrolysate, which the community strongly disfavors as non-bioequivalent. The biological complexity of true cerebrolysin (BDNF/NGF/GDNF-like peptides + free amino acids from enzymatic proteolysis) cannot be meaningfully replicated by US lyophilized vendors. FDA enforcement against peptide vendors (Dec 2024 warning letter, Summit Research Peptides) is increasing.
| Test | When | Target |
|---|---|---|
| Renal function (serum creatinine / eGFR) | Before starting first course; annually if repeating courses | eGFR >60 mL/min/1.73m² for unrestricted use; caution at 30–60; avoid below 30 |
| Neurological status assessment (for stroke/TBI use) | Baseline, Day 7, Day 14, Day 21, and 30/60/90 days post-course | — |
| Cognitive self-assessment log (community use) | Daily during course; weekly post-course for 3 months | — |
Severe renal impairment is a contraindication: Cerebrolysin is renally cleared and accumulation risk is elevated with impaired GFR.
Track functional recovery using NIHSS (stroke) or GCS/GOS (TBI) to quantify treatment response against published benchmarks.
No validated biomarker for cognitive enhancement in healthy adults: subjective tracking of memory, focus, verbal fluency, and sleep quality is the primary endpoint for community protocols.
Initial neuroprotective effects begin. Some users report improved alertness and mental energy within the first week.
Improved mental clarity, focus, and working memory. Neurotrophic signaling pathways are upregulated.
Peak cognitive benefits: enhanced memory consolidation, faster recall, and improved attention span. End of standard course.
Benefits persist for weeks to months after completing a course due to structural neuroplastic changes (increased synaptic density).
Days 1 to 3: Neuroprotective signaling kicks in immediately. BDNF and neurotrophic pathways upregulate with the first doses. Community users describe a pronounced mental sharpness or "brain reboot" feeling, sometimes within hours. This is also when transient dizziness, warmth, mild agitation, and headache are most likely; they typically resolve by Day 3 or 4 without intervention. Days 4 to 7: Sustained neurotrophic factor activity is building. Synaptogenesis signaling starts, and neuroinflammation begins to decrease. Users report improved mental energy, faster processing speed, and better verbal fluency. Working memory improvements become noticeable. The acute "sharpness" from injection days starts settling into something more baseline. Weeks 2 to 3: This is the peak window during the active course. Clinical trial data shows significant NIHSS improvement in stroke patients and ADAS-cog gains in Alzheimer's patients within this timeframe. Community users describe their best cognitive performance here: stronger memory consolidation, faster recall, reduced cognitive fatigue. Many report this as the best their brain has felt in years. Post-course, weeks 4 to 8: The course is over, but the biology isn't finished. Structural neuroplastic changes (synaptic density increases, dendritic spine remodeling) continue developing as the biological result of upregulated BDNF and NGF. Many users report peak effects arriving 4 to 6 weeks after the last injection. Benefits feel less like an acute boost and more like a genuine shift in baseline cognition. Post-course, months 2 to 3: Neuroplastic benefits plateau. Endogenous neurotrophic factor levels drift back toward baseline while the structural changes persist. Most users describe a lasting upward shift in cognitive baseline. Some fading becomes noticeable by month 3, which is the typical signal that it's time to consider repeating the course after the minimum 3-month break.
Neuroprotective mechanisms begin; BDNF and neurotrophic signaling pathways upregulated acutely after first doses.
Pronounced acute effect on injection days described as mental sharpness or a "brain reboot" sensation. Some users report feeling the injection within minutes to hours.
Sustained neurotrophic factor upregulation; synaptogenesis signaling initiating; neuroinflammation reduction beginning.
Improved mental energy, processing speed, and verbal fluency. Working memory improvements beginning. The "sharpness" from injection days becoming more baseline.
Clinical trial data (NIHSS improvement in stroke; ADAS-cog improvement in AD) reaches significance in this window for most studied indications. Peak neurotrophic signaling.
Memory consolidation and recall speed improvements peak. Enhanced attention span and reduced cognitive fatigue. Many users describe this as the best their brain has felt in years.
Structural neuroplastic changes (increased synaptic density, dendritic spine remodeling) continue to develop post-course as the biological substrate of upregulated BDNF/NGF.
Many users report peak effects arriving 4–6 weeks after the last injection: not during the course itself. Benefits feel "more real" and integrated into baseline cognition.
Neuroplastic benefits plateau; endogenous neurotrophic factor levels return toward baseline while structural changes persist.
Lasting cognitive improvement that most users describe as a permanent upward shift in baseline: though some fading is noted by month 3, which is the typical rationale for repeating the course.
Source: Estimated from peptide component kinetics; composite mixture effect ~2-4 hours
Loading the interactive decay curve.
Cerebrolysin is not FDA-approved for any indication in the United States. It is classified as a research compound. Purchasing and possessing it for personal research use exists in a legal grey area similar to other non-scheduled research peptides. The product is approved and prescribed clinically in over 40 countries, primarily across Europe (Austria, Germany, Russia), Asia (China, South Korea), and Latin America. EBEWE / EVER Neuro Pharma (Austria) is the sole manufacturer of the clinically validated pharmaceutical product. US-based users typically import EBEWE ampoules from international vendors. This constitutes personal importation of an unapproved drug, which carries customs seizure risk. No criminal prosecution precedent exists for personal-quantity imports, but seizure and non-delivery are real possibilities that buyers should factor into their planning. US domestic vendors selling lyophilized "cerebrolysin" powder offer a fundamentally different product from the EBEWE ampoules studied in all clinical trials. These are not bioequivalent. Cerebrolysin is not currently listed as a WADA-prohibited substance for competitive athletes, but injectable peptide preparations may fall under the S0 category of unapproved substances. Athletes should verify status with their sport's governing body. This content is for educational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
